Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

BioGaia AB (BGLA) Stock Price & Analysis

3 Followers

BGLA Stock Chart & Stats

€10.87-€0.27(-2.42%)
At close: 5:30 PM GMT+1
€10.5€11Aug 25Oct 13Oct 15Nov 2
Day’s Range
EUR 10.87 - EUR 10.87
52-Week Range
EUR 8.76 - EUR 12.32
Previous Close
EUR 11.14
Volume
N/A
Average Volume (3M)
43
Market Cap
EUR 1.12B
Enterprise Value
EUR 11.38B
Total Cash (Recent Filing)
EUR 518.27M
Total Debt (Recent Filing)
EUR 0
Price to Earnings (P/E)
31.6
Beta
0.15
Next Earnings
Feb 12, 2027 (Est.)
EPS Estimate
0.1
Next Dividend Ex-Date
N/A
Dividend Yield
1.38%

Bulls Say, Bears Say

Bulls Say

High Profitability

BioGaia’s consistently high gross and EBIT margins indicate a profitable business model with substantial operating economics. This profitability can support investment in products, clinical positioning, and distribution while providing resilience if revenue growth moderates over the next several quarters.

Conservative Balance Sheet

Minimal debt materially reduces refinancing and interest-rate exposure, preserving financial flexibility for investment, shareholder returns, or resilience during weaker demand. Strong ROE despite limited leverage also indicates that profitability is being generated efficiently rather than primarily through borrowing.

Long-term Revenue Growth

Multi-year revenue expansion, together with continued TTM growth, supports evidence of sustained demand for BioGaia’s probiotic offerings. Ongoing top-line progress can strengthen operating scale, deepen market presence, and provide a foundation for continued earnings generation.

Bears Say

Free Cash Flow Deterioration

Although cash conversion remains healthy in absolute terms, the recent decline in free cash flow weakens the trend in internally generated funds. If sustained, this could reduce the capacity available for product development, distributions, or other strategic uses of cash.

Margin Compression

Lower net margins indicate that BioGaia is retaining less profit from each unit of revenue than in earlier periods. Continued compression could limit earnings growth even if sales expand, and may reflect cost, mix, or spending pressures that require sustained management attention.

Reduced Asset And Equity Base

The decline in total assets and equity leaves BioGaia with a somewhat smaller balance-sheet base than at its prior peak. While leverage remains exceptionally low, a reduced capital cushion can modestly limit financial flexibility and the resources supporting future expansion.

BioGaia AB News

BGLA FAQ

What was BioGaia AB’s price range in the past 12 months?
BioGaia AB lowest stock price was €8.76 and its highest was €12.32 in the past 12 months.
What is BioGaia AB’s market cap?
BioGaia AB’s market cap is €1.12B.
When is BioGaia AB’s upcoming earnings report date?
BioGaia AB’s next earnings report is estimated for Feb 12, 2027 (not yet confirmed), which is in 94 days.
How were BioGaia AB’s earnings last quarter?
BioGaia AB released its earnings results on Jul 17, 2026. The company reported €0.092 earnings per share for the quarter, missing the consensus estimate of €0.095 by -€0.003.
Is BioGaia AB overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does BioGaia AB pay dividends?
BioGaia AB does not currently pay dividends.
What is BioGaia AB’s EPS estimate?
BioGaia AB’s EPS estimate is 0.10.
How many shares outstanding does BioGaia AB have?
BioGaia AB has 98,497,170 shares outstanding.
What happened to BioGaia AB’s price movement after its last earnings report?
BioGaia AB reported an EPS of €0.092 in its last earnings report, missing expectations of €0.095. Following the earnings report the stock price went down -0.449%.
Which hedge fund is a major shareholder of BioGaia AB?
Currently, no hedge funds are holding shares in DE:BGLA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology